Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Kreutz, Martin ^a,b   Giquel, Benoit ^b   Hu, Qin ^b   Abuknesha, Ram ^c   Uematsu, Satoshi ^d   Akira, Shizuo ^d   Nestle, Frank O ^a   Diebold, Sandra S ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD205 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; LYMPHOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN; OVALBUMIN; PHOSPHATE BUFFERED SALINE; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DOSAGE FORM COMPARISON; DRUG SPECIFICITY; DRUG TARGETING; IMMUNE RESPONSE; INNATE IMMUNITY; MELANOMA; MOUSE; NONHUMAN; TUMOR IMMUNITY; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIGENS; ANTIGENS, CD; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; IMMUNOCONJUGATES; LECTINS, C-TYPE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PEPTIDES; RECEPTORS, CELL SURFACE; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9;

MURINAE;

EID: 84863664792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040208     Document Type: Article

References (47)

1. Caminschi I, Lahoud MH, Shortman K, (2009) Enhancing immune responses by targeting antigen to DC. Eur J Immunol 39: 931-938.
2. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627-1638.
3. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004) In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 199: 815-824.
4. Wang H, Griffiths MN, Burton DR, Ghazal P, (2000) Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci U S A 97: 847-852.
5. Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, et al. (2005) Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol 42: 979-985.
6. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF, (2006) Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1. J Immunol 177: 2276-2284.
7. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF, (2006) Induction of CD8+ T cell responses through targeting of antigen to Dectin-2. Cell Immunol 239: 87-91.
8. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, et al. (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118: 2098-2110.
9. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, et al. (2008) The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood 112: 3264-3273.
10. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, et al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107-111.
11. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, et al. (2011) Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 108: 2384-2389.
12. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, et al. (2008) The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 105: 2574-2579.
13. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, et al. (2008) Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112: 1231-1239.
14. Bozzacco L, Trumpfheller C, Huang Y, Longhi MP, Shimeliovich I, et al. (2010) HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol 40: 36-46.
15. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, et al. (2005) Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice. Cancer Res 65: 7007-7012.
16. Johnson TS, Mahnke K, Storn V, Schonfeld K, Ring S, et al. (2008) Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 14: 8169-8177.
17. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, et al. (2009) The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci 1174: 6-17.
18. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779.
19. Kanzler H, Barrat FJ, Hessel EM, Coffman RL, (2007) Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13: 552-559.
20. Diebold SS, (2008) Determination of T-cell fate by dendritic cells. Immunol Cell Biol 86: 389-397.
21. Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, et al. (2005) Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 106: 2424-2432.
22. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192.
23. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, et al. (2009) Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 113: 377-388.
24. Maurer T, Heit A, Hochrein H, Ampenberger F, O'Keeffe M, et al. (2002) CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 32: 2356-2364.
25. Blander JM, Medzhitov R, (2006) Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440: 808-812.
26. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, et al. (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33: 827-833.
27. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, et al. (2010) Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207: 1261-1271.
28. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, et al. (2002) Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 3: 499.
29. Roberts TL, Sweet MJ, Hume DA, Stacey KJ, (2005) Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 174: 605-608.
30. Waibler Z, Anzaghe M, Konur A, Akira S, Muller W, et al. (2008) Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC. Eur J Immunol 38: 3127-3137.
31. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, et al. (2000) Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 18: 509-514.
32. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, et al. (2003) Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells. J Immunol 170: 2802-2805.
33. Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, et al. (2003) Most lymphoid organ dendritic cell types are phenotypically and functionally immature. Blood 102: 2187-2194.
34. Burgdorf S, Lukacs-Kornek V, Kurts C, (2006) The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 176: 6770-6776.
35. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C, (2008) Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 9: 558-566.
36. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, et al. (1995) The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375: 151-155.
37. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC, (2010) Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. J Immunol 185: 3426-3435.
38. Kimura Y, Sonehara K, Kuramoto E, Makino T, Yamamoto S, et al. (1994) Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J Biochem 116: 991-994.
39. Zhu FG, Reich CF, Pisetsky DS, (2001) The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. Immunology 103: 226-234.
40. Tirapu I, Giquel B, Alexopoulou L, Uematsu S, Flavell R, et al. (2009) PolyI:C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation. Int Immunol 21: 871-879.
41. Clynes RA, Towers TL, Presta LG, Ravetch JV, (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
42. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG, (2004) Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 64: 4357-4365.
43. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, et al. (2010) Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 144: 118-126.
44. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, et al. (2011) Targeted delivery of Toll-like receptor ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118: 6836-6844.
45. (1989) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Cancer Metastasis Rev 8: 82-88.
46. Pear WS, Nolan GP, Scott ML, Baltimore D, (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90: 8392-8396.
47. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, et al. (2010) Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists. Blood 115: 1949-1957.